Literature DB >> 11249591

Effectiveness of fluoroquinolones against gram-positive bacteria.

K Bush1, R Goldschmidt.   

Abstract

Fluoroquinolones are broad-spectrum and therapeutically effective antibacterial agents that have retained high activity against methicillin-susceptible Staphylococcus aureus (MSSA) and streptococci. Primary targets of these agents in Gram-positive bacteria are DNA topoisomerase and DNA gyrase. High-level resistance is associated with at least two mutations in either target, or combinations of at least two mutations in multiple targets, particularly affecting the ParC subunit of topoisomerase IV and the GyrA subunit of DNA gyrase. This resistance may be enhanced when combined with mutations that increase fluoroquinolone efflux. Data from fluoroquinolone-resistant clinical isolates suggest that as yet unidentified mutations may also be involved in clinical resistance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11249591

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  4 in total

1.  Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.

Authors:  Heather J Adam; Kristen N Schurek; Kimberly A Nichol; Chris J Hoban; Trish J Baudry; Nancy M Laing; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

2.  Phosphine-Initiated General-Base-Catalyzed Quinolone Synthesis.

Authors:  San Khong; Ohyun Kwon
Journal:  Asian J Org Chem       Date:  2014-04       Impact factor: 3.319

3.  Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.

Authors:  Heather J Smith; Michael Walters; Tamiko Hisanaga; George G Zhanel; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

4.  Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada.

Authors:  Samir N Patel; Roberto Melano; Allison McGeer; Karen Green; Donald E Low
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-01-18       Impact factor: 3.944

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.